Amgen Inc at Goldman Sachs Global Healthcare Conference Transcript
Okay. Great. I think we're going to get started, but thanks for joining us for our session with Amgen. I'm Terence Flynn, one of the biotech analysts here at Goldman, and we're very pleased to have Dave Reese, who's Executive Vice President of R&D for Amgen. And with that, I'm going to turn it over to Dave for some opening remarks, and then we'll dive into questions.
Well, thanks, Terence. It's a pleasure to be here today. Let me just make a few comments about our approach to R&D. I've been the head of R&D for just about a year now. And how do I conceptualize R&D in our industry as it exists now and projecting out 10 or 15 years? Well, to me, there are 2 core existential problems that we need to solve. One of them is how do we improve the success rates? Currently, they still run around 8% and it's been that way for some time. That varies by therapeutic areas, but we must do better. And then two, how do we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
